Journal article
Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions
R Murphy, S Green, G Ritter, L Cohen, D Ryan, W Woods, M Rubira, J Cebon, ID Davis, A Sjolander, A Kypridis, H Kalnins, M McNamara, MB Moloney, J Ackland, G Cartwright, J Rood, G Dumsday, K Healey, D Maher Show all
Preparative Biochemistry and Biotechnology | TAYLOR & FRANCIS INC | Published : 2005
DOI: 10.1081/PB-200054732
Abstract
The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A. Copyrigh..
View full abstract